6-K
GSK plc (GSK)
6-K
2025-02-26
For: 2025-02-26
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2025
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Dr Hal Barron | ||
| b) | Position/status | Non-Executive<br>Director | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of notional ADSs within Dr Barron's GSK Executive<br>Supplemental Savings Plan account following the reinvestment of<br>dividends | ||
| c) | Price(s)<br>and<br><br><br>volume(s) | Price(s) | Volume(s) | |
| $36.6400 | 3,269.946 | |||
| d) | Aggregated<br><br><br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2025-02-21 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Hal Barron | ||
| b) | Position/status | Non-Executive<br>Director | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of ADSs within Dr Barron's GSK 401(k) plan account<br>following the reinvestment of dividends | ||
| c) | Price(s)<br>and<br><br><br>volume(s) | Price(s) | Volume(s) | |
| $36.6400 | 83 | |||
| d) | Aggregated<br><br><br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2025-02-21 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | James Ford | ||
| b) | Position/status | SVP and<br>Group General Counsel, Legal and Compliance | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br><br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of notional ADSs within Mr Ford's GSK Executive<br>Supplemental Savings Plan account following the reinvestment of<br>dividends | ||
| c) | Price(s)<br>and<br><br><br>volume(s) | Price(s) | Volume(s) | |
| $36.6400 | 60.846 | |||
| d) | Aggregated<br><br><br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2025-02-21 | ||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | James Ford | ||
| b) | Position/status | SVP and<br>Group General Counsel, Legal and Compliance | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31<br>¼ pence each<br>('Ordinary Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Sale of 10,400 Ordinary Shares | ||
| c) | Price(s)<br>and<br><br><br>volume(s) | Price(s) | Volume(s) | |
| £14.5541 | 10,400 | |||
| d) | Aggregated<br><br><br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2025-02-25 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Emma Walmsley | ||
| b) | Position/status | Chief Executive Officer | ||
| c) | Initial<br>notification/amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br><br><br><br>ISIN: GB00BN7SWP63 | ||
| b) | Nature<br>of the transaction | Gift of<br>ordinary shares to family member for nil consideration | ||
| c) | Price(s)<br>and<br><br><br>volume(s) | Price(s) | Volume(s) | |
| £0.00 | 123,700 | |||
| d) | Aggregated<br><br><br>information | N/A (single transaction) | ||
| Aggregated<br>volume<br><br><br>Price | ||||
| e) | Date<br>of the transaction | 2025-02-21 | ||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: February<br>26, 2025 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |